Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

75.300
+2.2503.08%
Volume:281.00K
Turnover:20.82M
Market Cap:22.51B
PE:-39.42
High:75.600
Open:73.050
Low:72.150
Close:73.050
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:0.68
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.81
PE(LYR):-39.42
PS:23.07

Loading ...

Keymed Biosciences receives US$257.00 million from Ouro Medicines divestment; Gilead–Lakefront alliance to steer CM336/OM336 development

Bulletin Express
·
Jun 05

Keymed Biosciences: No Share Capital Changes in May 2026, Public Float Remains Sufficient

Bulletin Express
·
Jun 02

Movement Alert|CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan

Market Focus
·
May 29

Industrial Securities Initiates Coverage on KEYMED BIO-B with 'Buy' Rating, Citing Pipeline Value Reassessment

Stock News
·
May 18

Keymed Bio Monthly Return: Share Capital Steady at 298.74 Million; Public Float Meets 25% Threshold

Bulletin Express
·
May 06

Keymed Biosciences Sets 26 June 2026 for AGM; Proposes Director Re-election, EY Reappointment and General Mandates

Bulletin Express
·
Apr 29

Keymed Biosciences Inc.2025年业绩亮相:营收7.163亿元创新高,多元化研发助力商业化拓展

Bulletin Express
·
Apr 29

Keymed Biosciences publishes 2025 annual report

Reuters
·
Apr 29

Keymed Biosciences announces annual general meeting

Reuters
·
Apr 29

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

Keymed Biosciences issues supplemental disclosure on Ouro Medicines stake disposal

Reuters
·
Apr 15

KEYMED BIO-B Surges Nearly 8% in Afternoon Trading Following Gilead's Acquisition of Ouro

Stock News
·
Apr 15

KEYMED BIO-B (02162) Rises Nearly 6% Again as CMG313 Sales Accelerate and Global Value Pathway Clarifies

Stock News
·
Apr 02

KEYMED BIO-B Reports Unchanged Share Capital and Confirms Public Float Compliance for March 2026

Bulletin Express
·
Apr 01

A Look At Keymed Biosciences (SEHK:2162) Valuation After Annual Results And Commercialization Progress

Simply Wall St.
·
Mar 29

Keymed Biosciences (SEHK:2162) Loss Narrowing In 1H 2025 Tests Premium Growth Narrative

Simply Wall St.
·
Mar 28

Keymed Biosciences' Loss Deepens in 2025

MT Newswires Live
·
Mar 27

KeyMed Biosciences Announces 2025 Annual Results and Business Updates

THOMSON REUTERS
·
Mar 26

KEYMED BIO-B Reports Widened Annual Loss Amid Revenue Growth

Stock News
·
Mar 26

KeyMed Biosciences FY Revenue RMB 716.3 Million

THOMSON REUTERS
·
Mar 26